Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
Go back to Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026| Corcept Therapeutics, Inc. (NASDAQ: CORT) | Delayed: 79.71 -0.2 (0.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.91 | 52 Week High | $10.00 | |||
| Open | $80.70 | 52 Week Low | $3.22 | |||
| Day High | $82.00 | P/E | N/A | |||
| Day Low | $77.38 | EPS | $-0.46 | |||
| Volume | 882,745 | |||||
